Stock News

Merck stock up slightly after FDA approves Recarbrio for new indication
UPDATE 2-Merck's treatment for urinary, abdominal infections gets FDA approval
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available

As seen on...